Certolizumab Pegol for Plaque Psoriasis: 2-Year Efficacy Results from 2 Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

Authors

K Gordon
K Reich
A Blauvelt
D Thaci
C Leonardi
Y Poulin
Marion Boehnlein
Sarah Kavanagh
Catherine ArendtFollow
Alice B. Gottlieb, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

10-2019

Journal Title

Journal of the American Academy of Dermatology

Department

Dermatology

Recommended Citation

Gordon, K., Reich, K., Blauvelt, A., Thaci, D., Leonardi, C., Poulin, Y., Boehnlein, M., Kavanagh, S., Arendt, C., & Gottlieb, A. B. (2019). Certolizumab Pegol for Plaque Psoriasis: 2-Year Efficacy Results from 2 Phase 3 Trials (CIMPASI-1 and CIMPASI-2). Journal of the American Academy of Dermatology, 81 (4 Suppl. 1), AB195. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/282